C₁₅H₁₀Cl₂N₂O₂ (P274)
Quantities
| P4250 | defined daily dose | 2.5 |
| P2067 | mass | 320.011933 |
| P3780 | active ingredient in | ... | Q47521205 (Ativan) | Ativan |
| P233 | canonical SMILES | String | C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl | ??? |
| P373 | Commons category | String | Lorazepam | ??? |
| P1343 | described by source | ... | Q316572 (Opium Law) | Opium Law |
| P1889 | different from | ... | Q411806 (loprazolam) | loprazolam |
| P703 | found in taxon | ... | Q10998 (potato) | potato |
| P703 | found in taxon | ... | Q161098 (Triticum aestivum) | Triticum aestivum |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P8026 | LiverTox likelihood score | ... | Q83284667 (LiverTox toxicity likelihood category E) | LiverTox toxicity likelihood category E |
| P176 | manufacturer | ... | Q206921 (Pfizer) | Pfizer |
| P1987 | MCN code | String | 2933.91.42 | ??? |
| P2175 | medical condition treated | ... | Q127076 (vomiting) | vomiting |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q501571 (catatonia) | catatonia |
| P2175 | medical condition treated | ... | Q544006 (anxiety disorder) | anxiety disorder |
| P2175 | medical condition treated | ... | Q3184856 (substance abuse) | substance abuse |
| P2175 | medical condition treated | ... | Q7140388 (focal epilepsy) | focal epilepsy |
| P2175 | medical condition treated | ... | Q2157462 (schizophreniform disorder) | schizophreniform disorder |
| P2175 | medical condition treated | ... | Q980709 (status epilepticus) | status epilepticus |
| P2175 | medical condition treated | ... | Q1869874 (insomnia) | insomnia |
| P2175 | medical condition treated | ... | Q19000444 (neurotic disorder) | neurotic disorder |
| P2175 | medical condition treated | ... | Q54972453 (sleep-wake disorder) | sleep-wake disorder |
| P129 | physically interacts with | ... | Q21118909 (G protein-coupled receptor 68) | G protein-coupled receptor 68 |
| P129 | physically interacts with | ... | Q21982979 (Alpha-1B adrenergic receptor) | Alpha-1B adrenergic receptor |
| P3489 | pregnancy category | ... | Q3679261 (Australian pregnancy category C) | Australian pregnancy category C |
| P3489 | pregnancy category | ... | Q28123618 (US pregnancy category D) | US pregnancy category D |
| P769 | significant drug interaction | ... | Q55434 (pethidine) | pethidine |
| P769 | significant drug interaction | ... | Q58614 (loxapine) | loxapine |
| P769 | significant drug interaction | ... | Q81225 (morphine) | morphine |
| P769 | significant drug interaction | ... | Q176533 (alfentanil) | alfentanil |
| P769 | significant drug interaction | ... | Q174723 (codeine) | codeine |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q303646 (hydromorphone) | hydromorphone |
| P769 | significant drug interaction | ... | Q377270 (dihydrocodeine) | dihydrocodeine |
| P769 | significant drug interaction | ... | Q407241 (phenobarbital) | phenobarbital |
| P769 | significant drug interaction | ... | Q407592 (tramadol) | tramadol |
| P769 | significant drug interaction | ... | Q221361 (clozapine) | clozapine |
| P769 | significant drug interaction | ... | Q407535 (oxycodone) | oxycodone |
| P769 | significant drug interaction | ... | Q407541 (fentanyl) | fentanyl |
| P769 | significant drug interaction | ... | Q407721 (buprenorphine) | buprenorphine |
| P769 | significant drug interaction | ... | Q414463 (tapentadol) | tapentadol |
| P769 | significant drug interaction | ... | Q417915 (sufentanil) | sufentanil |
| P769 | significant drug interaction | ... | Q420383 (primidone) | primidone |
| P769 | significant drug interaction | ... | Q421930 (mirtazapine) | mirtazapine |
| P769 | significant drug interaction | ... | Q2622907 (periciazine) | periciazine |
| P769 | significant drug interaction | ... | Q55186498 ((±)-thiopental) | (±)-thiopental |
| P769 | significant drug interaction | ... | Q7553347 (sodium oxybate) | sodium oxybate |
| P9989 | stylized name | String | LORazepam | ??? |
| P279 | subclass of | ... | Q83871 (benzodiazepine drug) | benzodiazepine drug |
| P2868 | subject has role | ... | Q35456 (essential medicine) | essential medicine |
| P2868 | subject has role | ... | Q62903 (anxiolytic) | anxiolytic |
| P2868 | subject has role | ... | Q575136 (antiemetic) | antiemetic |
| P2868 | subject has role | ... | Q576618 (anticonvulsant agent) | anticonvulsant agent |
| P2868 | subject has role | ... | Q72941151 (developmental toxicant) | developmental toxicant |
| P2868 | subject has role | ... | Q17164853 (GABAA receptor positive allosteric modulators) | GABAA receptor positive allosteric modulators |
| P2868 | subject has role | ... | Q50377192 (hypnotics and sedatives) | hypnotics and sedatives |
| P2868 | subject has role | ... | Q50430260 (GABA Modulators) | GABA Modulators |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | lorazepam | ??? |
Why not click here or view trends?
log id: 4494736